Related Experiment Video
Updated: Sep 29, 2025
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Choosing Kinase Inhibitors for Androgen Deprivation Therapy-Resistant Prostate Cancer
Shangwei Zhong1,2, Shoujiao Peng1,2, Zihua Chen1
1Department of General Surgery, Xiangya Hospital, Central South University, Hunan 410008, China.
Abstract:
Androgen deprivation therapy (ADT) is a systemic therapy for advanced prostate cancer (PCa). Although most patients initially respond to ADT, almost all cancers eventually develop castration resistance. Castration-resistant PCa (CRPC) is associated with a very poor prognosis, and the treatment of which is a serious clinical challenge. Accumulating evidence suggests that abnormal expression and activation of various kinases are associated with the emergence and maintenance of CRPC. Many efforts have been made to develop small molecule inhibitors to target the key kinases in CRPC. These inhibitors are designed to suppress the kinase activity or interrupt kinase-mediated signal pathways that are associated with PCa androgen-independent (AI) growth and CRPC development. In this review, we briefly summarize the roles of the kinases that are abnormally expressed and/or activated in CRPC and the recent advances in the development of small molecule inhibitors that target kinases for the treatment of CRPC.
Insights
Androgen deprivation therapy resistance in prostate cancer (PCa) leads to castration-resistant PCa (CRPC). Targeting abnormal kinases with small molecule inhibitors offers a promising strategy for treating advanced PCa.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Advanced prostate cancer (PCa) often becomes castration-resistant (CRPC) despite initial response to androgen deprivation therapy (ADT).
- Castration-resistant PCa (CRPC) presents a significant clinical challenge with a poor prognosis.
- Aberrant kinase expression and activation are implicated in the development and progression of CRPC.
Purpose of the Study:
- To review the roles of kinases in CRPC.
- To summarize recent advancements in small molecule kinase inhibitors for CRPC treatment.
Main Methods:
- Literature review of studies on kinase roles in CRPC.
- Review of recent developments in small molecule kinase inhibitors targeting CRPC.
Main Results:
- Kinases play critical roles in the androgen-independent growth and survival of CRPC cells.
- Several small molecule inhibitors targeting specific kinases have shown potential in preclinical and clinical studies.
Conclusions:
- Targeting aberrant kinases is a key strategy in managing CRPC.
- Ongoing research into small molecule kinase inhibitors holds promise for improving CRPC treatment outcomes.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:34Inhibition of Cdk Activity
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:15M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
03:03mTOR Signaling and Cancer Progression
The mTOR pathway or the...